IMST integrates Radiation Performance for LoRa Certification with Keysight
About one year ago, IMST was selected as an accredited LoRa™ Alliance certification test house for LoRaWAN™ certification. “The Certification testing against LoRaWAN V1.0.1 is a success story with more and more end-devices becoming available that have been certified”, said Derek Hunt, Chairman of the LoRa Alliance Certification Committee. However the possibility of connecting an end-device to an operator’s network successfully also depends on the quality of the radio implementation of the end-device.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160919005974/en/
LoRa certification measuring chamber (Photo: Business Wire)
“Operators should impose minimum end-device radio performance criteria to be able to ensure consistent service to all end-users. A way to achieve this is to add radiation performance measurements to the product test cycle”, says Markus Ridder, Head of the Test Department at IMST.
The test setup for the radiation performance was developed and tested in close cooperation with Keysight Technologies.
From a regulatory point of view the main requirement for 868 MHz ISM devices is that the device’s ERP should not radiate in excess of +14 dBm (or 25 mW) for any orientation. This sets the upper bound on the end-device radiated power and also includes the duty cycle restrictions. In general, with the measured effective TRP (Total Radiated Power) the first quality characteristic of an end device can be derived.
“The operator needs to ensure that the end device actually radiates as much power as possible to maximize the robustness and usable data rate of the uplink”, says Mats Hansen from DIGIMONDO, who operate the first public LoRaWAN network in Germany. “In addition a measurement of the device’s receiver performance is required”, states Hansen. This is derived from the fact that LoRaWAN networks are symmetrical, bi-directional networks implying that the receiver performance of the end-device is also important.
For this the TIS (Total Isotropic Sensitivity) is measured, allowing for bi-directional performance characterisation of the end device.
Both measurements are performed in the accredited radio metrology laboratory at IMST. The software required on the end-devices is already installed on the end device if it has already passed the LoRaWAN Certification, which can also be performed in IMST laboratories.
The report that IMST provides as the output from LoRaWAN Radiation Performance measurement gives antenna diagrams showing the minimum and maximum values for the TRP and TIS. Based on these figures, a network operator can grade devices and ensure a good and smooth network availability and performance. Within development these measurements would help manufacturer to improve their designs.
Ruud Schellekens, CEO of 1M2M said:”We like to base our development on facts. IMST’s LoRa measurement reports give us just that!”
Are you interested in our certification services for your LoRa wireless solutions?
If so, contact us at firstname.lastname@example.org.
IMST GmbH is a leading design house and development centre for wireless modules, communication systems, chip design, antennas, EDA software and regulatory certification which uses an in-house certified regulatory test centre. IMST offers a standard product portfolio of radio modules with hardware/software as well as complete system and product design services. Individualised support during every phase of product development including wireless technologies, from initial consulting to series production, is one of the unique selling propositions of IMST. For more information, visit http://www.imst.com
About Keysight Technologies
Keysight is an US company that manufactures test and measurement equipment and software. In 2014, Keysight was spun off from Agilent Technologies, bringing with it the product lines focused on electronics and radio, leaving Agilent with the chemical and bio-analytical products.
About LoRa™ Alliance
The LoRa™ Alliance is an open, non-profit association has grown to over 370 members since its inception in March 2015, becoming one of the largest and fastest growing alliances in the technology sector. Its members are closely collaborating and sharing their experience to promote the LoRaWAN™ protocol as the leading open global standard for secure, carrier-grade IoT LPWA connectivity. With the technical flexibility to address the multiple IoT applications, both static and mobile, and a certification program to guarantee interoperability, LoRaWAN™ has already being deployed by major mobile network operators globally and is anticipated to widely expand in 2016. www.lora-alliance.org
Mr. Markus Ridder
+49 2842 981-384
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and